Phaseline

Companies › Adverum Biotechnologies

Adverum Biotechnologies: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 2; Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ixo-vec (ixoberogene soroparvovec)
Intravitreal gene therapy expressing soluble fms-like tyrosine kinase-1 (sFlt-1), a VEGF t
FLT1Phase 3Neovascular Age-Related Macular Degeneration (nAMD); Neovascular Age-Related Macular Degeneration (nAMD) Wet AMDDec 2026
ADVM-022
AAV gene therapy expressing aflibercept (VEGF inhibitor)
VEGFAPhase 2Neovascular Age-related Macular DegenerationAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06856577Ixo-vec (ixoberogene soroparvovec)Phase 3Neovascular Age-Related Macular Degeneration (nAMD)OphthalmologyDec 2026
NCT07482176Ixo-vec (ixoberogene soroparvovec)Phase 3Neovascular Age-Related Macular Degeneration (nAMD)OphthalmologyNov 2027
NCT05536973ADVM-022Phase 2Neovascular Age-related Macular DegenerationOphthalmologyAug 2028
NCT07630649Ixo-vec (ixoberogene soroparvovec)Phase 2Neovascular Age-Related Macular Degeneration (nAMD) Wet AMDOphthalmologyJun 2031

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

FLT1 (1) VEGFA (1)

Companies with the same targets

Roche AstraZeneca Jiangsu HengRui Medicine Hutchmed Jiangsu Simcere Pharmaceutical Chengdu Origen Biotechnology Merck & Co. (MSD) Takeda AO GENERIUM Chipscreen Biosciences

Companies built like this

Innostellar Biotherapeutics jCyte MeiraGTx Ocular UK Tecnoquimicas NovaSight

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.